The Indian Medical Association (IMA) has expressed serious concerns regarding the use of the newly introduced GLP-1 medication in India. The association plans to submit a memorandum to the Central government advocating for stricter regulations on its prescription to prevent misuse. The GLP-1 drug has entered the Indian pharmaceutical market at a considerably lower price point compared to existing alternatives.

Call for Restricted Prescriptions

Dr. Anil Kumar J. Nayak, the President of the IMA, stated that the organization intends to recommend limiting prescriptions of GLP-1 drugs to certified endocrinologists, diabetologists, or doctors specializing in general medicine. The growing trend of using this medication primarily for weight loss raises significant concerns, as the drug was developed for managing diabetes. Dr. Nayak emphasized that taking any modern allopathic medication without professional medical guidance can be hazardous.

Potential Health Risks

During an official statement, Dr. Nayak highlighted the potential side effects associated with GLP-1 drugs, which include gastric disturbances, nausea, vomiting, diarrhea, and, in some cases, pancreatitis. He cautioned that the misuse of this medication could potentially be fatal due to the rare risk of thyroid cancer. He reiterated the necessity of consulting an MD physician, diabetologist, or endocrinologist before using this medication.

Increased Vigilance from Drug Regulators

In response to the growing concerns surrounding the sale of weight loss drugs, the Drug Regulator has enhanced surveillance on the distribution of GLP-1 medications. This includes rigorous monitoring of the drug supply chain to combat unauthorized sales and misuse. Recent inspections targeted a total of 49 entities, involving online pharmacies, wholesalers, retailers, and wellness clinics, with notices issued for any irregularities observed in sales and promotional practices.

Impact of Patent Expiry on Drug Pricing

Following the expiration of patents for GLP-1 medications, which are primarily used for treating type 2 diabetes and obesity, several major pharmaceutical companies have rolled out more affordable generic alternatives. These generics are being offered at significantly reduced prices, making them more accessible to the public. However, this increased availability has raised alarms regarding their sale without proper medical oversight, as improper use could lead to serious health complications.

Public Health Implications

The IMA cautions that the unchecked availability of these medications through retail channels and online platforms could pose significant health risks when used without appropriate medical supervision. The ongoing monitoring and regulatory measures are critical to ensuring public health safety and preventing any associated negative health outcomes stemming from the misuse of weight loss drugs.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share